Summary by Moomoo AI
ALPHAMAB-B, a subsidiary of Kangning Jerui Biopharmaceutical, submitted a disclosure report on September 3, 2024, disclosing changes in company shares. The report shows that the company repurchased 360,000 ordinary shares on September 3, 2024, at a repurchase price ranging from HKD 2.48 to HKD 2.55 per share, with a total expenditure of HKD 908,520. After this share buyback, the company's issued shares decreased to 963,901,807 shares, while treasury shares increased to 1,022,000 shares. According to regulations, the company is not allowed to issue new shares or sell or transfer any treasury shares within 30 days after the share buyback without the approval of the exchange. This share buyback was carried out in accordance with the repurchase authorization passed at the shareholder meeting on June 12, 2024. The authorization allows the company to repurchase up to 96,492,380 shares.
